Chemomab Therapeutics (STU:2QV0) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Chemomab Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was €0.00 Mil. Chemomab Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Chemomab Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Chemomab Therapeutics's current FCF Yield % is -86.81%.

The historical rank and industry rank for Chemomab Therapeutics's FCF Margin % or its related term are showing as below:

STU:2QV0's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -127.22
* Ranked among companies with meaningful FCF Margin % only.

Chemomab Therapeutics FCF Margin % Historical Data

The historical data trend for Chemomab Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics FCF Margin % Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Chemomab Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Chemomab Therapeutics's FCF Margin %

For the Biotechnology subindustry, Chemomab Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Chemomab Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Chemomab Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-14.694	/	0
	=	%

Chemomab Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	%

Chemomab Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CMMB:USA

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines